Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Tel Aviv
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Biocancell Ltd

+ Add to Watchlist

BICL:IT

95.80 ILs 1.20 1.24%

As of 10:24:29 ET on 06/01/2015.

Snapshot for Biocancell Ltd (BICL)

Open: 100.00 Day's Range: 93.70 - 100.00 Volume: 15,171
Previous Close: 97.00 52wk Range: 91.40 - 260.40 1-Yr Rtn: -62.34%

Stock Chart for BICL

No chart data available.
  • BICL:IT 95.20
  • 1D
  • 1M
  • 1Y
97.00
Interactive BICL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BICL

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. TA-100 -
Earnings Per Share (ttm) -0.8904
Est. EPS -
Est. PEG Ratio -
Market Cap (M ILS) 46.84
Shares Outstanding (M) 48.89
30 Day Average Volume 60,284
Price/Book (mrq) 1.6961
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BICL

  • Revenue
  • Net Income (M/ILS)
  • Profit Margin (%)

Company Profile & Key Executives for BICL

BioCancell Ltd. is a biopharmaceutical company that develops targeted cancer therapy treatments for numerous types of cancer. The treatment is based on utilizing a target gene, such as the H19 gene, an oncofetal gene expressed at high levels in over 40 types of human cancer tissues, while existing at a nearly undetectable level in the surrounding normal tissues.

Jonathan BurginChief Executive OfficerAvraham HochbergChief Scientist/Co-Founder
Monique Ben-AmVP:Clinical Development
More Company Profile & Key Executives for BICL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil